A message from Pearl Pugh
Head of North America
"What an incredible moment—my very first IDWeek! I am genuinely excited to meet and connect with so many inspiring leaders and experts within the infectious disease community. IDWeek is a terrific opportunity to exchange knowledge, showcase the latest breakthroughs, and engage in meaningful conversations. This year, ViiV Healthcare will present 15 abstracts featuring new real-world data, long-term efficacy results, and patient perspectives. These results demonstrate the impact of our leading and innovative portfolio of long-acting injectables and two-drug regimens for the treatment and prevention of HIV. The work we’re doing isn’t just about advancing science—it’s about providing real choices for people living with HIV and people who can benefit from PrEP. ViiV Healthcare’s unwavering commitment to our mission drives us to relentlessly advance our efforts, collaborate closely with the community, and boldly set new standards in HIV care. And We Won’t Stop until we end the epidemic, once and for all. Looking forward to meeting at IDWeek 2025!"
Learn more about ViiV Healthcare’s sponsored and supported studies
Title |
First Author |
Presentation Details |
|---|---|---|
| Cabotegravir for HIV Treatment | ||
| PREFER-LA: Improved Adherence and Viral Control in Real-world Study of People with HIV (PWH) in the United States with Adherence Challenges on Oral Antiretroviral Therapy (ART) Switching to Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) |
W. Short |
Oral Presentation Wednesday, Oct. 22 |
| Few Differences in Persistence and Virologic Outcomes Across Age Groups Among Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Users: Findings from the OPERA Cohort | M. Sension | Poster Monday, Oct. 20 |
| Reasons For Discontinuation of Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) for HIV Treatment in the OPERA Cohort: A CHORUS Survey of Healthcare Providers | R. Hsu | Poster Monday, Oct. 20 |
| Prevalence of Integrase HIV-1 Drug Resistance Mutations in the United States: 2019-2024 | C. Henegar | Poster Monday, Oct. 20 |
| PREFER-LA: People with HIV (PWH) in the United States with Prior Adherence Challenges with Oral Antiretroviral Therapy (ART) Prefer Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Therapy After Switch | Z. Henry | Poster Monday, Oct. 20 |
| Cabotegravir for HIV PrEP | ||
| Human Immunodeficiency Virus (HIV) Testing and Evidence of HIV Among Real-World Long-Acting Pre-Exposure Prophylaxis (LAI-PrEP) Users in a United States Claims Database: Results from the PrEPFACTS Study | A. Metzner | Oral Presentation Wednesday, Oct. 22 |
| Associations Between Intersectional Stigma and Long-Acting Injectable Prep (LAI-PrEP) Willingness and Preference Among Gay, Bisexual, and Other Men Who Have Sex with Men (GBMSM) | J. Glick | Poster Monday, Oct. 20 |
| Characteristics Associated with HIV Pre-Exposure Prophylaxis Persistence Among Men Who Have Sex with Men in the United States: Results from the American Men’s Internet Survey (AMIS) 2023-24 | D. Islek | Poster Monday, Oct. 20 |
| Screening Practices for HIV and Sexually Transmitted Infections During Cabotegravir Long-Acting or Daily Oral Pre-Exposure Prophylaxis Use in the US | S. Barnett | Poster Monday, Oct. 20 |
| Black Women’s Experiences on Long-Acting Cabotegravir for PrEP: Interim Patient Findings from the EBONI Study | K. Nelson | Poster Monday, Oct. 20 |
| Dolutegravir | ||
| Polypharmacy, Drug-Drug Interactions, and Risk of Hospitalization Among Veterans with HIV Taking 2-, 3-, and 4-Drug Antiretroviral Therapy Regimens | L. Yan | Poster Monday, Oct. 20 |
| Real-World Effectiveness and Safety Outcomes in People with HIV-1 Switching to Dolutegravir + Lamivudine (DTG+3TC) with Unknown Prior Genotype: a Systematic Literature Review and Meta-Analysis | J. Boulos |
Poster Monday, Oct. 20 |
| The Global REGAL Cohort: A Retrospective Real-World Study of the Effectiveness and Tolerability of the Antiretroviral Treatment Regimens DTF/3TC Compared to BIL/FTC/TAF in Older Persons Living with HIV | J. Fraysse |
Poster Monday, Oct. 20 |
| The US REGAL Cohort: A Retrospective Real-World Study of the Effectiveness and Tolerability of the Antiretroviral Regimens DTG/3TC Compared to BIC/FTC/TAF in Older Persons Living with HIV | O. Ogbuagu |
Poster Monday, Oct. 20 |
| Pipeline | ||
| The Clinical Development of VH3810109 (N6LS): Advancing Ultra-Long-Acting HIV Treatment into the Future | P. Leone |
Poster Monday, Oct. 20 |
Explore our symposium and learning lounge events
In addition to our scientific data presented at IDWeek 2025, ViiV Healthcare is excited to host one Learning Lounge and one Medical Symposium, focused on long-acting injectables for HIV treatment and prevention.
Title |
Speakers / Moderators |
Date, Time and Location |
|---|---|---|
Learning Lounge PrEP today: Data discussions on an HIV-1 PrEP option |
Speakers
Moderator: Robert Morris, PharmD, North American Medical Director, HIV Prevention, ViiV Healthcare |
Tuesday, Oct. 21 11:15 – 12 p.m. ET Learning Lounge 1 – Georgia World Congress Center |
Medical Symposium Unlocking the Potential of Long-Acting Injectable Therapies for HIV Prevention and Treatment |
Speakers
|
Tuesday, Oct. 21 7 - 8 a.m. ET International Ballroom D |
OUR STORIES: SCIENCE AND INNOVATION
To lift the substantial burdens of daily treatment and social stigma associated with HIV, a cure is essential to accomplishing our goal of ending the HIV epidemic. With this goal in mind, we are in pursuit of a cure for HIV.
Collaboration is the key to finding solutions to HIV challenges – and it’s at the heart of what we do at our HIV research facility in Branford, Connecticut.
Women make up more than half of all people living with HIV – why are they under-represented in studies of new medicines?
